Advisory Committees

Briefing Information for the July 12, 2017 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance.

FDA

Novartis Pharmaceuticals Corp.

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Page Last Updated: 07/10/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English